ANGLE Inks Deal for Advanced Cancer Sequencing Tech
Company Announcements

ANGLE Inks Deal for Advanced Cancer Sequencing Tech

ANGLE plc (GB:AGL) has released an update.

ANGLE plc has entered into an agreement with NuProbe to attain an exclusive license for a next-generation sequencing (NGS) assay, enhancing the capabilities of its liquid biopsy technology, Parsortix. The NGS panel, which facilitates the analysis of both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample, promises to advance cancer treatment personalization. This collaboration aims to bolster ANGLE’s pharma services and offer clinicians tools for ongoing monitoring of tumor dynamics and patient response to therapies.

For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskANGLE plc Highlights Advances in Liquid Biopsy Technology
TipRanks UK Auto-Generated NewsdeskANGLE plc Advances Cancer Treatment with Dual Analysis
TipRanks UK Auto-Generated NewsdeskANGLE plc’s Breakthrough in Prostate Cancer CTC Profiling
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App